Samir Al Moghazi Selected Research

Osteoprotegerin

1/2016	Higher Levels of Osteoprotegerin and Immune Activation/Immunosenescence Markers Are Correlated with Concomitant Bone and Endovascular Damage in HIV-Suppressed Patients.
1/2014	Immune activation, immunosenescence, and osteoprotegerin as markers of endothelial dysfunction in subclinical HIV-associated atherosclerosis.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Samir Al Moghazi Research Topics

Disease

4	COVID-19 01/2021 - 10/2020
3	Thrombophlebitis 10/2018 - 01/2018
2	Endocarditis 10/2018 - 10/2018
1	Hypertension (High Blood Pressure) 01/2021
1	Kidney Diseases (Kidney Disease) 01/2021
1	Pneumonia (Pneumonitis) 10/2018
1	Infections 10/2018
1	Lung Abscess 10/2018
1	Critical Illness (Critically Ill) 01/2018
1	Inflammation (Inflammations) 01/2016
1	Cardiovascular Diseases (Cardiovascular Disease) 01/2016
1	Atherosclerosis 01/2014

Drug/Important Bio-Agent (IBA)

2	C-Reactive ProteinIBA 01/2021 - 10/2020
2	carbapenemaseIBA 10/2018 - 10/2018
2	ceftazidime drug combination avibactamIBA 10/2018 - 10/2018
2	OsteoprotegerinIBA 01/2016 - 01/2014
1	Lopinavir FDA Link 01/2021
1	cobicistat mixture with darunavirIBA 01/2021
1	Heparin (Liquaemin)FDA LinkGeneric 01/2021
1	Hydroxychloroquine (Plaquenil)FDA LinkGeneric 01/2021
1	Protease Inhibitors (Protease Inhibitor)IBA 01/2021
1	Ritonavir (Norvir)FDA Link 01/2021
1	Ertapenem (Invanz)FDA Link 10/2018
1	ProcalcitoninIBA 01/2018

Therapy/Procedure

3	Therapeutics 10/2018 - 01/2014